Journal
PEDIATRIC PULMONOLOGY
Volume 51, Issue 2, Pages 115-132Publisher
WILEY
DOI: 10.1002/ppul.23304
Keywords
primary ciliary dyskinesia; PCD; kartagener; consensus statement; PCD Foundation
Categories
Funding
- National Institutes of Health (NIH) [U54HL096458, 5R01HL071798]
- Genetic Disorders of Mucociliary Clearance is a part of the NCATS Rare Diseases Clinical Research Network (RDCRN) [U54HL096458]
- RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS
- CTSA NIH/NCATS UNC [ULTR000083]
- CTSA NIH/NCATS Colorado [UL1TR000154]
- Intramural Research Program of NIH/NIAID
Ask authors/readers for more resources
Primary ciliary dyskinesia (PCD) is a genetically heterogeneous, rare lung disease resulting in chronic oto-sino-pulmonary disease in both children and adults. Many physicians incorrectly diagnose PCD or eliminate PCD from their differential diagnosis due to inexperience with diagnostic testing methods. Thus far, all therapies used for PCD are unproven through large clinical trials. This review article outlines consensus recommendations from PCD physicians in North America who have been engaged in a PCD centered research consortium for the last 10 years. These recommendations have been adopted by the governing board of the PCD Foundation to provide guidance for PCD clinical centers for diagnostic testing, monitoring, and appropriate short and long-term therapeutics in PCD patients. (C) 2015 The Authors. Pediatric Pulmonology Published by Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available